Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 1/20 | 0.76 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.55 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.55 |
| ▸ | MGLL | Q99685 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531007 | 0.96 | BCL9 (0.76) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL531155 | 0.95 | BCL9 (0.73) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL530771 | 0.95 | BCL9 (0.73) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL570540 | 0.95 | BCL9 (0.73) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL7079988 | 0.95 | BCL9 (0.73) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL8643816 | 0.94 | BCL9 (0.68) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL957930 | 0.93 | BCL9 (0.81) | BCL9CTNNB1GAAPTPN7PTPN12 | |
| SCHEMBL19170303 | 0.92 | BCL9 (0.69) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL9657255 | 0.90 | BCL9 (0.68) | BCL9CTNNB1GAAEGFRERBB2 | |
| SCHEMBL4746640 | 0.90 | BCL9 (0.68) | BCL9CTNNB1GAAEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5801221-A | EXPOSURE OF MONOMER SOLUTION TO FORM PATTERNS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-09-01 | — | — | US | claimed |
| EP-0697906-B1 | ARTIFICIAL RECEPTORS, ANTIBODIES, AND ENZYMES | MASSACHUSETTS INST TECHNOLOGY (US) | 1998-08-26 | — | — | EP | claimed |
| US-9822353-B2 | PEGylated aspartyl-tRNA synthetase polypeptides | ATYR PHARMA, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9714419-B2 | PEGylated tyrosyl-tRNA synthetase polypeptides | ATYR PHARMA, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9255156-B2 | Immunogenic synthetic glycoconjugate for the immunotherapy of melanoma | AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (IT) | 2016-02-09 | — | — | US | disclosed |
| US-20150159148-A1 | PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES | ATYR PHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20140255378-A1 | PEGYLATED TYROSYL-TRNA SYNTHETASE POLYPEPTIDES | ATYR PHARMA, INC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140161806-A1 | IMMUNOGENIC SYNTHETIC GLYCOCONJUGATE FOR THE IMMUNOTHERAPY OF MELANOMA | AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (Italian Hospital) (IT) | 2014-06-12 | — | — | US | disclosed |
| US-8680043-B2 | Synthetic immunogenic glycoconjugate for melanoma immunotherapy | AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI (IT) | 2014-03-25 | — | — | US | disclosed |
| WO-2013086228-A1 | PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES | ATYR PHARMA, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013022982-A2 | PEGYLATED TYROSYL-TRNA SYNTHETASE POLYPEPTIDES | ATYR PHARMA, INC. (US) | 2013-02-14 | — | — | WO | disclosed |
| EP-2021141-A2 | BIODEGRADABLE WATER SOLUBLE POLYMERS | Medivas, LLC (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20070282011-A1 | Biodegradable water soluble polymers | MEDIVAS, LLC (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007133616-A2 | BIODEGRADABLE WATER SOLUBLE POLYMERS | MEDIVAS, LLC (US) | 2007-11-22 | — | — | WO | disclosed |
| US-5801221-A | EXPOSURE OF MONOMER SOLUTION TO FORM PATTERNS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0697906-B1 | ARTIFICIAL RECEPTORS, ANTIBODIES, AND ENZYMES | MASSACHUSETTS INST TECHNOLOGY (US) | 1998-08-26 | — | — | EP | disclosed |
| EP-0697906-A4 | ARTIFICIAL RECEPTORS, ANTIBODIES, AND ENZYMES | MASSACHUSETTS INST TECHNOLOGY (US) | 1996-07-17 | — | — | EP | disclosed |
| EP-0697906-A1 | ARTIFICIAL RECEPTORS, ANTIBODIES, AND ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1996-02-28 | — | — | EP | disclosed |
| WO-1994026381-A1 | ARTIFICIAL RECEPTORS, ANTIBODIES, AND ENZYMES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-11-24 | — | — | WO | disclosed |
| US-4489710-A | Composition and method for transplantation therapy | XOMA CORPORATION (US) | 1984-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150159148-A1 | PEGYLATED ASPARTYL-TRNA SYNTHETASE POLYPEPTIDES | AARS1, GARS1, DARS1 | BCL9 4458/4885CTNNB1 4872/4885GAA 198/4885 |
| US-20140161806-A1 | IMMUNOGENIC SYNTHETIC GLYCOCONJUGATE FOR THE IMMUNOTHERAPY OF MELANOMA | CD47, CD4, CD14 | BCL9 928/4885CTNNB1 3849/4885GAA 370/4885 |
| US-20070282011-A1 | Biodegradable water soluble polymers | PHOSPHO1, PEF1, PEBP1 | BCL9 602/4885CTNNB1 1770/4885GAA 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.